Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non-muscle-invasive Bladder Cancer: A Propensity Score-matched Analysis.
Fukuokaya W, Kimura T, Miki J, Kimura S, Watanabe H, Bo F, Okada D, Aikawa K, Ochi A, Suzuki K, Shiga N, Abe H, Egawa S. Fukuokaya W, et al. Among authors: abe h. Clin Genitourin Cancer. 2020 Apr;18(2):e55-e61. doi: 10.1016/j.clgc.2019.09.005. Epub 2019 Sep 27. Clin Genitourin Cancer. 2020. PMID: 31630978
Red cell distribution width predicts time to recurrence in patients with primary non-muscle-invasive bladder cancer and improves the accuracy of the EORTC scoring system.
Fukuokaya W, Kimura T, Miki J, Kimura S, Watanabe H, Bo F, Okada D, Aikawa K, Ochi A, Suzuki K, Shiga N, Abe H, Egawa S. Fukuokaya W, et al. Among authors: abe h. Urol Oncol. 2020 Jul;38(7):638.e15-638.e23. doi: 10.1016/j.urolonc.2020.01.016. Epub 2020 Mar 15. Urol Oncol. 2020. PMID: 32184059
Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
Fukuokaya W, Kimura T, Yanagisawa T, Kimura S, Tsuzuki S, Koike Y, Iwamoto Y, Enei Y, Tanaka M, Urabe F, Onuma H, Honda M, Miki J, Oyama Y, Abe H, Egawa S. Fukuokaya W, et al. Among authors: abe h. BJU Int. 2021 Jan;127(1):90-95. doi: 10.1111/bju.15176. Epub 2020 Aug 6. BJU Int. 2021. PMID: 32662189
Bladder cancer invasion along a tension-free vaginal mesh.
Ochi A, Harada S, Fukuokaya W, Honma K, Huang T, Abe H. Ochi A, et al. Among authors: abe h. IJU Case Rep. 2021 Jan 21;4(2):104-107. doi: 10.1002/iju5.12254. eCollection 2021 Mar. IJU Case Rep. 2021. PMID: 33718818 Free PMC article.
Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma.
Fukuokaya W, Kimura T, Yanagisawa T, Kimura S, Tsuzuki S, Koike Y, Iwamoto Y, Enei Y, Tanaka M, Urabe F, Onuma H, Honda M, Miki J, Oyama Y, Abe H, Egawa S. Fukuokaya W, et al. Among authors: abe h. Cancer Immunol Immunother. 2022 Jan;71(1):229-236. doi: 10.1007/s00262-021-02980-x. Epub 2021 Jun 8. Cancer Immunol Immunother. 2022. PMID: 34100985 Free PMC article.
Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer.
Tsuzuki S, Kawano S, Fukuokaya W, Mori K, Nishikawa H, Tashiro K, Watanabe D, Uchimoto T, Nishimura K, Yano Y, Murakami M, Koike Y, Hata K, Koide H, Miki J, Abe H, Yamada H, Naruoka T, Sugaya S, Kimura T, Tomita M, Nakajo H, Egawa S. Tsuzuki S, et al. Among authors: abe h. Jpn J Clin Oncol. 2021 Nov 1;51(11):1665-1671. doi: 10.1093/jjco/hyab115. Jpn J Clin Oncol. 2021. PMID: 34296282
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
Fukuokaya W, Kimura T, Komura K, Uchimoto T, Nishimura K, Yanagisawa T, Imai Y, Iwatani K, Ito K, Urabe F, Tsuzuki S, Kimura S, Terada N, Mukai S, Oyama Y, Abe H, Kamoto T, Azuma H, Miki J, Egawa S. Fukuokaya W, et al. Among authors: abe h. Urol Oncol. 2022 Jul;40(7):346.e1-346.e8. doi: 10.1016/j.urolonc.2022.02.020. Epub 2022 Mar 26. Urol Oncol. 2022. PMID: 35346571
5,328 results